Founded in 2013 in Lund, Sweden, MedVasc focuses on Solutio, a single-use anesthesia catheter that enables safe, painless and accurate tumescent anesthesia during thermal ablation of varicose veins. The device is compatible with standard RF and laser fibers used worldwide, aiming to increase clinician control and patient comfort in chronic venous disorder procedures. Solutio has already completed production and testing activities and is now progressing toward FDA clearance, with U.S. market approval targeted for autumn 2026. The company participates in the SmiLe incubator programme, leveraging a life-science venture hub that has helped over 110 startups raise more than €1.05 billion. Financially, MedVasc has relied on shareholder support, raising €917k in May 2025 and an additional €2.2 million in the latest round, signalling continued confidence from its investor base. The fresh capital will fund remaining regulatory, validation and commercial-readiness milestones ahead of a U.S. launch.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2026